The NOAC market with ₩230 billion is fluctuating
By Kim, Jin-Gu | translator Choi HeeYoung
22.01.27 06:20:38
가나다라
0
Generic for Eliquis was withdrawn from the market by Supreme Court ruling, original reflective profit
After the expiration of Xarelto's material patent
Lixiana surpassed 80 billion won a year, Pradaxa has prolonged sluggishness, and joint sales ended
▲Lixiana, Pradaxa, Xarelto, Eliquis (clockwise from the top left)
The NOAC market, which has grown to 230 billion won, has fluctuated due to generic drugs. After the Supreme Court ruling, Eliquis enjoyed reflective benefits as generics were withdrawn altogether. On the other hand, in the case of Xarelto, as generic products were released one after another due to the expiration of material patents, it seems to have slowed down somewhat. Lixiana maintained its No. 1 position in the market last year by repeating rapid growth. It was found that prescription performance decreased for the fourth consecutive year due to the prolonged slump in Pradaxa.◆ Lixiana's annual prescription amount of increased by 16% year-on-year
According to UBIST, the size of
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)